Plasma glycated CD59 (gCD59), a Novel Biomarker for the Diagnosis, Management and Follow up of Women with Gestational Diabetes (GDM).
Wellcome Trust
National University of Ireland, Galway
The frequency of diabetes diagnosed during pregnancy is increasing. The diagnosis for diabetes in pregnancy (DIP) is very long, cumbersome and inconvenient for most women. CD59 is a new blood test that has been shown to be more elevated in people with diabetes than in people without diabetes. The purpose of this study is to examine if this new blood test can predict the development of DIP (the blood test will be done in the first trimester of pregnancy), can diagnose DIP (the blood test will be done in the second trimester of pregnancy at the same time with the current diagnosis test), can predict pregnancy-related complications for both mother and baby, can asses the efficacy of treatment in DIP (the blood test will be done in the third trimester of pregnancy) and can predict the development of diabetes after delivering the baby (the blood test will be done at the 6 weeks follow-up for all women with DIP). This new proposal addresses a major public health concern, is supported by previous research on human indicating that CD59 is a new emerging blood test with large potential to diagnose and monitor DIP
4.1 Discovery and preclinical testing of markers and technologies